SE0301963D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0301963D0
SE0301963D0 SE0301963A SE0301963A SE0301963D0 SE 0301963 D0 SE0301963 D0 SE 0301963D0 SE 0301963 A SE0301963 A SE 0301963A SE 0301963 A SE0301963 A SE 0301963A SE 0301963 D0 SE0301963 D0 SE 0301963D0
Authority
SE
Sweden
Prior art keywords
conhr
coor
cor
so2r
new compounds
Prior art date
Application number
SE0301963A
Other languages
Swedish (sv)
Inventor
Britt-Marie Swahn
Niklas Plobeck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301963A priority Critical patent/SE0301963D0/en
Publication of SE0301963D0 publication Critical patent/SE0301963D0/en
Priority to PCT/SE2004/001080 priority patent/WO2005003123A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

The present invention relates to new compounds of formula (I) wherein R is R<3>, R<5>, R<6>, COR<5>, COR<6>, CONHR<3>, CONHR<5>, CONHR<6>, CON(R<6>)2, COOR<5>, COOR<6>, SO2R<5>, SO2R<6>, OR<3>, OCOR<3>, COOR<3>, COR<3>, CONR<3>R<4>, NHCOR<3>, NR<3>R<4>, NHSO2R<3>, SO2R<3>, SO2NR<3>R<4>, SR<3>, CN, halogeno or NO2; R<1> is aryl or heteroaryl each of which is optionally substituted with one or more of fluoro or chloro; R<2> is R<5>, R<6>, COR<5>, COR<6>, CONHR<5>, CONHR<6>, CON(R<6>)2, COOR<5>, or COOR<6>; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
SE0301963A 2003-07-02 2003-07-02 New compounds SE0301963D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0301963A SE0301963D0 (en) 2003-07-02 2003-07-02 New compounds
PCT/SE2004/001080 WO2005003123A1 (en) 2003-07-02 2004-07-01 Novel pyridine derivatives as jnk specific inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301963A SE0301963D0 (en) 2003-07-02 2003-07-02 New compounds

Publications (1)

Publication Number Publication Date
SE0301963D0 true SE0301963D0 (en) 2003-07-02

Family

ID=27731089

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301963A SE0301963D0 (en) 2003-07-02 2003-07-02 New compounds

Country Status (2)

Country Link
SE (1) SE0301963D0 (en)
WO (1) WO2005003123A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888374B2 (en) * 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
WO2008082487A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CA2716898A1 (en) * 2008-02-27 2009-09-03 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
BRPI0916576A2 (en) * 2008-08-04 2017-06-27 Chdi Inc at least one chemical entity, pharmaceutical composition, and method for treating a condition or disorder.
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
MX2012002752A (en) * 2009-09-04 2012-04-19 Novartis Ag Heteroaryl compounds as kinase inhibitors.
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
SG182534A1 (en) 2010-01-25 2012-08-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011110612A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
MX364378B (en) 2011-08-30 2019-01-21 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
EP2751086A4 (en) 2011-08-30 2015-09-16 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2017000779A (en) 2014-07-17 2017-07-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
WO2005003123A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
SE0203654D0 (en) New compounds
SE0301963D0 (en) New compounds
SE0200979D0 (en) New compounds
HUP0202248A2 (en) Compounds useful as anti-inflammatory agents
PA8550101A1 (en) DERIVATIVES OF BENZAMIDA TIAZOL AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS, AND METHODS FOR USE
ME00328B (en) Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
SE0102439D0 (en) New compounds
ES2195785B1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
DK1625126T3 (en) Imidazo and thiazolopyridines as JAK3 kinase inhibitors
UY27222A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
NO20044731L (en) Quinoline and Isoquinoline Derivatives Process for Preparation thereof and its Use as Inflammatory Inhibitors
NO20063231L (en) Pyrido [2,3-D] pyrimidine-2,4-diamines as PDE 2 inhibitors
HUP0402352A2 (en) Pyrimidine derivatives for use as phosphodiesterase (pde)7 inhibitors and pharmaceutical compositions containing them
UY28059A1 (en) NEW DERIVATIVES OF DIHYDROPIRIMIDO (4,5-D) PYRIMIDONE REPLACED BY AMINO. MANUFACTURE AND USE OF THE SAME AS PHARMACEUTICAL AGENTS.
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
PT1263724E (en) NEW COMPOUNDS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
SE0100569D0 (en) New compounds
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
DE60039359D1 (en) AMIDE AS PYRUVATDEHYDROGENASE INHIBITORS
EA200700144A1 (en) PYRIDOPYRIMIDINE DERIVATIVES, THEIR RECEIVING, THEIR APPLICATION IN THERAPY
TW200606164A (en) New compounds
RS53211B (en) PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES, PROCES FOR THEIR PREPRATION AND THEIR THERAPEUTICAL USE
SE0101322D0 (en) Novel compounds
SE0302546D0 (en) New compounds